Aptevo Therapeutics Inc. announced that the Company has filed a provisional patent with the U.S. Patent and Trademark Office pertaining to an anti-PD-L1 x anti-CD40 compound, APVO711, with the potential to fight a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma, and carcinomas of the lung, gastrointestinal tract and colon. The Company plans to initiate pre-clinical studies this year.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.746 USD | +5.65% | 0.00% | -91.13% |
Apr. 11 | US Equity Markets Close Mixed After March Producer Price Inflation Data | MT |
Apr. 11 | Top Midday Decliners | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-91.13% | 1.13M | |
-2.20% | 103B | |
+1.78% | 95.28B | |
+1.46% | 22.15B | |
-15.61% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.80% | 16.05B | |
+5.11% | 13.68B | |
+36.14% | 12.17B |
- Stock Market
- Equities
- APVO Stock
- News Aptevo Therapeutics Inc.
- Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors